Sepsis and septic shock have been notoriously difficult indications for drug development. However, considering the high incidence of sepsis, associated high mortality, and vast unmet needs, this indication offers considerable market opportunity for pharmaceutical and biotechnology manufacturers able to develop effective therapies. Sepsis and Septic Shock is a new study from Decision Resources, Inc., that offers critical strategic analysis for companies seeking to benefit from an emerging sales opportunity for sepsis therapeutics in the billions of dollars.

  (Photo:  http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )    Novel Therapies Have Significant Commercial Potential 

No therapies are currently marketed to treat the inflammatory and coagulation disturbances associated with sepsis and septic shock. Because of the high unmet need, both in terms of mortality and cost (ICU care), the emerging therapies targeting these pathways have vast market potential. If these agents are approved, their novelty-as the first therapeutics ever to directly affect the outcome and mortality of severe sepsis and septic shock- will provide a strong impetus for considerable and rapid uptake.

Experts in all of the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are particularly enthusiastic about Eli Lilly's recombinant human activated protein C (rhAPC; Xigris) and indicate that this agent is likely to be the first market entry of an immunomodulator that directly targets the pathophysiology of septic shock. If the efficacy and safety shown in Phase III trials hold up in the wider clinical setting, Xigris will create a paradigm shift in the treatment of severe sepsis and septic shock-opening the door for a host of additional promising therapies in development that directly target the inflammatory or coagulation cascade.

Antibiotics Will Experience Modest Growth

The antibiotics market for sepsis is relatively mature, and will experience modest growth compared with emerging biologics targeting the inflammatory and coagulation cascade. The main areas of growth will be related to greater utilization of broad-spectrum agents that can be used as monotherapy (e.g., the fluoroquinolones and carbapenems) and strong uptake of agents effective against antibiotic-resistant bacteria (e.g., novel glycopeptides, fluoroquinolones).

Sepsis and Septic Shock is part of Infectious Disease, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2525 (fax), or sama@dresources.com.

In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be.

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X76783838

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,
sama@dresources.com

Decision Resources Study Evaluates Type 2 Diabetes Therapies in Early- and Late-Stage Development and Forecasts Their Commercial Potential

View Now